B3 · BRL
BIOM3
Biomm SA
- Day's range
- R$5.78 – R$6.10
- Day's volume
- R$336.7k
- 52-week range
- R$4.82 – R$10.39
Follow BIOM3 on Fuolio
See how BIOM3 weighs in your net worth, what it has paid you and how far it is from your target allocation.
Create a free accountBIOM3 in numbers
- Market cap
- R$834.8m
- P/E
- 27.53
- P/B
- 2.57
- Dividend yield (12m)
- 0.00%
- Net debt/EBITDA
- 1.50
BIOM3 trades at 27.53 times its earnings of the last 12 months.
BIOM3 price history
BIOM3 risk and return
Monthly closes adjusted for splits and distributions.
| Metric | 12 months | 36 months | 60 months |
|---|---|---|---|
| Return | -34.71% | +22.22% | -58.30% |
| Volatility (annualised) | 39.59% | 94.20% | 84.26% |
| Largest drawdown | -40.04% | -72.71% | -74.29% |
| Positive months | 4/12 | 13/36 | 19/60 |
How much did investing in BIOM3 return?
R$1,000.00 invested on 01/09/2021 would be worth R$417.05 today.
- Value today in BIOM3
- R$417.05
- Return over the period
- -58.30%
- Return per year
- -16.05%
- In the Ibovespa
- R$1,657.66
With dividends reinvested, before taxes and costs, at month-end closes. Past returns do not guarantee future ones.
BIOM3 fundamentals
Valuation
- P/E27.53
- P/B2.57
- EV/EBITDA16.64
- EV/EBIT19.85
- EV/Revenue2.39
- P/EBIT18.06
- P/S2.17
- P/OCF-11.01
- P/FCF-17.26
- Earnings yield5.04%
- PEG ratio0.18
- Earnings per shareR$0.22
- Book value per shareR$2.38
Debt
- Net debtR$82.6m
- Net debt/EBITDA1.50
- Net debt/Equity0.25
- Debt/Equity0.29
- Current ratio1.55
- Quick ratio0.48
- Cash ratio0.04
Efficiency
- Gross margin37.62%
- EBITDA margin14.34%
- Operating margin12.02%
- Net margin10.31%
- Asset turnover0.63
Profitability
- ROE9.33%
- ROA6.45%
- ROIC10.78%
- Payout0.00%
Growth
- Revenue CAGR (5 years)34.88%
- Earnings CAGR (5 years)—
- Revenue growth (year)88.45%
- Earnings growth (year)91.33%
- Revenue growth (quarter)176.51%
- Earnings growth (quarter)145.03%
What is BIOM3's fair price?
Two classic value formulas, with today's numbers. The current price is R$6.10.
- Graham's fair price
- R$3.44
- 43.57% below the price
√(22.50 × R$0.22 × R$2.38)
Benjamin Graham paid no more than a P/E of 15 and a P/B of 1.5. Their product, 22.5, times earnings (EPS) and book value per share gives the fair price.
- Bazin's ceiling price
- —
- Does not apply to BIOM3: it paid no distributions in the last five years.
Décio Bazin only bought shares yielding at least 6% a year in distributions. The ceiling price is the average dividend per share of recent years divided by 6%.
Graham ignores growth and debt; Bazin assumes past distributions will repeat. They are reference points for comparison, not a buy recommendation.
BIOM3 indicators by year
Multiples at each year's closing price; margins and returns from that year's accounts.
| Indicator | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| P/E | -147.76 | -17.52 | -9.04 | -4.83 | -11.50 | -13.60 | -13.05 | -8.82 |
| P/B | 3.15 | 5.15 | 5.96 | 2.81 | 8.27 | 5.03 | 4.74 | 3.54 |
| Earnings per share | -R$0.05 | -R$0.61 | -R$0.64 | -R$1.37 | -R$1.09 | -R$1.15 | -R$0.92 | -R$0.89 |
| Book value per share | R$2.29 | R$2.07 | R$0.97 | R$2.35 | R$1.52 | R$3.12 | R$2.53 | R$2.22 |
| ROE | -2.13% | -29.37% | -66.00% | -58.17% | -71.93% | -36.96% | -36.35% | -40.12% |
| ROIC | -1.37% | -33.74% | -32.55% | -37.76% | -27.29% | -23.38% | -25.73% | -21.50% |
| Gross margin | 31.55% | 12.51% | 19.68% | 15.24% | 25.15% | 23.75% | 5.83% | 15.64% |
| EBITDA margin | -1.95% | -56.83% | -61.36% | -82.17% | -61.30% | -94.72% | -588.22% | -2,230.78% |
| Net margin | -2.48% | -54.00% | -68.65% | -88.19% | -74.95% | -120.62% | -624.02% | -2,717.88% |
BIOM3 financial statements
| Line | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net revenue | R$269.3m | R$142.9m | R$118.2m | R$105m | R$107.1m | R$58.7m |
| Cost of sales | -R$184.3m | -R$125m | -R$94.9m | -R$89m | -R$80.2m | -R$44.7m |
| Gross profit | R$85m | R$17.9m | R$23.3m | R$16m | R$26.9m | R$13.9m |
| EBITDA | -R$5.2m | -R$81.2m | -R$72.5m | -R$86.2m | -R$65.6m | -R$55.6m |
| EBIT | -R$5.2m | -R$81.2m | -R$72.5m | -R$86.2m | -R$65.6m | -R$55.6m |
| Net finance result | -R$1.7m | R$4.6m | -R$8.3m | -R$7m | -R$14.1m | -R$15.1m |
| Profit before tax | -R$6.9m | -R$76.6m | -R$80.8m | -R$93.2m | -R$79.8m | -R$70.7m |
| Income tax | R$261k | -R$644k | -R$340k | R$630k | -R$475k | -R$63k |
| Net income | -R$6.7m | -R$77.2m | -R$81.1m | -R$92.6m | -R$80.3m | -R$70.8m |
Figures the company filed with the CVM. Debt excludes leases; each quarter is that quarter alone.
BIOM3 against its sector
The same indicators for the company's other shares and the sector's largest stocks.
| Stock | P/E | P/B | Dividend yield (12m) | ROE | Market cap |
|---|---|---|---|---|---|
| BIOM3Biomm | 27.53 | 2.57 | 0.00% | 9.33% | R$834.8m |
| HYPE3HYPERA S.A. | 9.87 | 1.19 | 4.42% | 12.10% | R$17.2bn |
| BLAU3BLAU FARMACÊUTICA S.A. | 10.68 | 1.07 | 8.43% | 10.02% | R$2.5bn |
| OFSA3OUROFINO S.A. | 5.88 | 1.68 | 5.01% | 28.55% | R$1.4bn |
| BALM3BAUMER S.A. | 9.76 | 1.28 | 21.91% | 13.16% | R$178.9m |
| BALM4BAUMER S.A. | 6.43 | 0.85 | 33.24% | 13.16% | R$178.9m |
Does BIOM3 pay dividends?
BIOM3 has no distributions on record.
About Biomm
- Sector
- Consumo Não Cíclico
- Segment
- Medicamentos e Outros Produtos
- Listing segment
- Level 2
- Tag along
- 100.00%
- Free float
- 72.38%
- Shares issued
- 136.85m ordinary
- Average daily trading
- R$263.1k
- Listed since
- 03/02/2014
- CNPJ
- 04.752.991/0001-10
A Biomm S.A. é uma empresa farmacêutica brasileira focada em biotecnologia, com atuação em desenvolvimento, produção e comercialização de medicamentos de alta complexidade. A companhia tem presença relevante em produtos para doenças crônicas, incluindo insulinas, e ampliou seu portfólio para outras especialidades com registro sanitário no país. Parte da estratégia é reduzir dependência de importação por meio de produção local e parcerias tecnológicas. Listada na B3 sob BIOM3, a empresa opera em um mercado regulado, com dependência de aprovação da Anvisa, acordos de fornecimento e acesso a canais institucionais e privados. O desempenho está ligado à execução industrial, escala comercial, mix de produtos e contratos com sistemas de saúde e distribuidores. Como companhia de biotecnologia, mantém investimento contínuo em desenvolvimento de portfólio e em estrutura produtiva para aumentar autonomia tecnológica no segmento farmacêutico nacional.
Investor website| Shareholder | Ordinary | Preferred | Total |
|---|---|---|---|
| Alaska Investimentos Ltda | 26.15% | 0.00% | 26.15% |
| BTGP GESTÃO | 12.20% | 0.00% | 12.20% |
| WALFRIDO SILVINO DOS MARES GUIA NETO | 5.53% | 0.00% | 5.53% |
| TMG/IBR L.P. | 5.44% | 0.00% | 5.44% |
| BNDES Participações - BNDESPAR | 5.12% | 0.00% | 5.12% |
| ITALO AURELIO GAETANI | 3.16% | 0.00% | 3.16% |
| Samos Participações Ltda. | 2.71% | 0.00% | 2.71% |
| TMG/IBR L.P. | 1.81% | 0.00% | 1.81% |
| Gama Participações Ltda. | 1.52% | 0.00% | 1.52% |
| Elbrus Participações Ltda. | 0.42% | 0.00% | 0.42% |
| Outros | 35.95% | 0.00% | 35.95% |
Questions about BIOM3
How much is BIOM3 today?
BIOM3 is at R$6.10 (3.74% on the day), last traded on 30/09/2026.
What are the P/E and P/B of BIOM3?
BIOM3 trades at a P/E of 27.53 and a P/B of 2.57.
How much did BIOM3 return in 12 months?
BIOM3 returned -34.71% in 12 months, with annualised volatility of 39.59% and a largest drawdown of -40.04%.
What sector is BIOM3 in?
Biomm is in the Consumo Não Cíclico sector, Medicamentos e Outros Produtos segment.